Julia B. A.
- Country
- Spain
- Department
- Dermatology
Research Overview
- Evaluation of GSK4527363 in Systemic Lupus Erythematosus and Healthy Participants, Including Chinese and Japanese Cohorts
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Subcutaneous Ianalumab (VAY736) Added to Standard Therapy in Systemic Lupus Erythematosus
- Phase 3 Randomized Double-blind Placebo-controlled Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Data & Insights
Has run more than one trial at 164 of 305 partner sites.
Specializations
Autoimmune and inflammatory rheumatic disease
María Barbado Ajo is involved in clinical research focused on systemic lupus erythematosus, including cutaneous lupus erythematosus, lupus nephritis, and idiopathic inflammatory myopathies such as dermatomyositis and polymyositis. Her work also extends to related immune-mediated conditions, reflecting a strong therapeutic interest in chronic inflammatory disease control.
- Systemic lupus erythematosus
- Cutaneous lupus erythematosus
- Lupus nephritis
- Dermatomyositis
- Polymyositis
Her clinical portfolio includes therapies directed at disease activity, skin involvement, and systemic manifestations in autoimmune disease.
Gastroenterology and hepatobiliary disease
Her research landscape includes Crohn's disease, ulcerative colitis, eosinophilic esophagitis, primary biliary cholangitis, and primary sclerosing cholangitis. This profile indicates active involvement in both inflammatory bowel disease and chronic liver disease.
- Crohn's disease
- Ulcerative colitis
- Eosinophilic esophagitis
- Primary biliary cholangitis
- Primary sclerosing cholangitis
Her therapeutic focus includes immune-modulating treatments for intestinal inflammation and cholestatic hepatobiliary disorders.
Ophthalmology and retinal disease
María Barbado Ajo is engaged in studies of neovascular age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal vein occlusion, geographic atrophy, and neurotrophic keratopathy. Her clinical trial activity also includes uveitis, highlighting a broad interest in retinal, corneal, and inflammatory eye disease.
- Neovascular age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion
- Geographic atrophy
- Neurotrophic keratopathy
Her work is aligned with therapies aimed at preserving vision and managing chronic retinal pathology.
Cardiometabolic, hematologic, and respiratory medicine
Her research includes hypertension, atherosclerotic cardiovascular disease, type 2 diabetes, elevated Lp(a), acute pulmonary embolism, and hemophilia A and hemophilia B. She is also involved in studies of chronic obstructive pulmonary disease, bronchiectasis, and acute hypoxemic respiratory failure, showing interest across vascular, metabolic, bleeding, and pulmonary disorders.
- Hypertension
- Type 2 diabetes
- Hemophilia A
- Hemophilia B
- Acute pulmonary embolism
Her clinical research activity spans cardiovascular risk reduction, metabolic control, coagulation disorders, and respiratory stabilization.
Internal medicine, oncology, neurology, and critical care
Within internal medicine, María Barbado Ajo also contributes to trials in Alzheimer’s disease-related agitation and psychosis, treatment-resistant depression, septic shock, critical condition, locally advanced colon cancer, resectable pancreatic adenocarcinoma, and non-muscle invasive bladder cancer. This reflects a wide therapeutic reach across neuropsychiatric, oncologic, and acute care settings.
- Alzheimer’s disease
- Treatment-resistant depression
- Septic shock
- Locally advanced colon cancer
- Non-muscle invasive bladder cancer
Her trial involvement includes therapies addressing neuropsychiatric symptoms, infection-related organ failure, and advanced malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
